Silvia Martini
University of Bologna
GeneCD3Docking (molecular)GenomeExpressed sequence tagAllosteric regulationReceptorStart codonEnzymeChemistryApoptosisIn vitroStop codonIn silicoSurvivinAromataseSequence (medicine)EstrogenImmunotherapyXPO1Growth inhibitionTriple-negative breast cancerAzoleCause of deathFemale populationDual modeCancer researchBreast cancerRational designGeneticsSequence analysisMedicineBlotBiologyCoding regionEctopic expressionDistribution (pharmacology)
5Publications
3H-index
27Citations
Publications 5
Newest
#1Silvia MartiniH-Index: 3
#2Valentina ZucoH-Index: 25
Last. Nadia ZaffaroniH-Index: 66
view all 10 authors...
Triple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Here, we pursued a combinatorial therapeutic approach to enhance the activity of selinexor, the first-in-class XPO1 inhibitor, by miR-34a ectopic expression in human TNBC experimental models. Anti-proliferative activity induced by selinexor and miR-34a expression, singly and in combination, was evaluated by MTS assay and cell counting. The effect of treatments on survivin and apoptosis-related protein...
Source
#1Silvia MartiniH-Index: 3
#2Mariangela FiginiH-Index: 26
Last. Alessandro SattaH-Index: 4
view all 12 authors...
Triple-negative breast cancer (TNBC) is an aggressive disease with poor prognosis and limited therapeutic options. Recent advances in the immunotherapy field have enabled the development of new treatment strategies, among which the use of bispecific antibodies (BsAbs), able to redirect T cells against tumors, has shown promising results. In particular, a BsAb that uses TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) as a target was constructed and demonstrated good results in redirec...
2 CitationsSource
#1Jessica Caciolla (UNIBO: University of Bologna)H-Index: 2
#2Angelo Spinello (SISSA: International School for Advanced Studies)H-Index: 16
Last. Alessandra Magistrato (SISSA: International School for Advanced Studies)H-Index: 30
view all 7 authors...
Breast cancer (BC) is the most diffused cancer type in women and the second leading cause of death among female population. Effective strategies to fight estrogen responsive (ER+) BC, which represe...
6 CitationsSource
#1Angelo Spinello (SISSA: International School for Advanced Studies)H-Index: 16
#2Silvia MartiniH-Index: 3
Last. Alessandra Magistrato (SISSA: International School for Advanced Studies)H-Index: 30
view all 10 authors...
Abstract Estrogens play a key role in cellular proliferation of estrogen-receptor-positive (ER+) breast cancers (BCs). Suppression of estrogen production by competitive inhibitors of the enzyme aromatase (AIs) is currently one of the most effective therapies against ER + BC. Yet, the development of acquired resistance, after prolonged treatments with AIs, represents a clinical major concern. Serendipitous findings indicate that aromatase may be non-competitively inhibited by clinically employed ...
14 CitationsSource
#1Allison Piovesan (UNIBO: University of Bologna)H-Index: 14
#2Maria Caracausi (UNIBO: University of Bologna)H-Index: 13
Last. Pierluigi Strippoli (UNIBO: University of Bologna)H-Index: 27
view all 10 authors...
The incomplete determination of the mRNA 5′ end sequence may lead to the incorrect assignment of the first AUG codon and to errors in the prediction of the encoded protein product. Due to the significance of the mouse as a model organism in biomedical research, we performed a systematic identification of coding regions at the 5′ end of all known mouse mRNAs, using an automated expressed sequence tag (EST)-based approach which we have previously described. By parsing almost 4 million BLAT alignme...
4 CitationsSource